International research networks in pediatric rheumatology: the PRINTO perspective
- 1 September 2004
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Rheumatology
- Vol. 16 (5), 566-570
- https://doi.org/10.1097/01.bor.0000130286.54383.ea
Abstract
Purpose of review The purpose of this review is to highlight the problems and possible solutions for the conduct of international collaborative research for pediatric rheumatic diseases. Recent findings Pediatric rheumatic diseases are rare conditions associated with important sequelae on the quality of life and long-term outcome. The research aimed at studying new therapeutic approaches is difficult because of logistic, methodological, and ethical problems. To face these problems, two international networks have been founded: the Pediatric Rheumatology Collaborative Study Group (or PRCSG) and the Paediatric Rheumatology international Trials Organization (or PRINTO). The two networks have the goal to promote, facilitate, and conduct high-quality research into pediatric rheumatic diseases. In particular they have been able to standardize the evaluation of response to therapy in juvenile idiopathic arthritis, juvenile systemic lupus erythematosus, and juvenile dermatomyositis; to draft clinical remission criteria in juvenile idiopathic arthritis; and to provide cross-cultural adapted and validated quality-of-life instruments like the Childhood Health Assessment Questionnaire and the Child Health Questionnaire in 32 different languages. Summary The creation of large international trial networks such as PRINTO and PRCSG, the definition of internationally recognized and standardized outcome measures and definitions of improvement, the validation of quality-of-life instruments, and the adoption of adequate legislative measures (pediatric rule) have created the basic premises for the best future assessment of pediatric rheumatic diseases. This progress now affords children with pediatric rheumatic diseases the same opportunities as adults to be treated with drugs whose safety and efficacy have been assessed through legitimate scientifically valid investigations.Keywords
This publication has 18 references indexed in Scilit:
- Pediatric rheumatology: a call to actionCurrent Opinion in Rheumatology, 2003
- Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositisRheumatology, 2003
- Sickle Cell Anemia — Basic Research Reaches the ClinicNew England Journal of Medicine, 1995
- Use of Placebo Controls in Clinical Trials DisputedScience, 1995
- Methotrexate treatment of recalcitrant childhood dermatomyositisArthritis & Rheumatism, 1992
- Auranofin in the treatment of juvenile rheumatoid arthritisArthritis & Rheumatism, 1990
- The N of 1 trials design in the rheumatic diseasesArthritis & Rheumatism, 1988
- Penicillamine and Hydroxychloroquine in the Treatment of Severe Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 1986
- Time course of response to nonsteroidal antiinflammatory drugs in juvenile rheumatoid arthritisArthritis & Rheumatism, 1984
- Auranofin in the treatment of juvenile rheumatoid arthritisThe Journal of Pediatrics, 1983